News

A Compassionate Use IDE allows access to an unapproved product for U.S. patients with serious or life-threatening conditions for whom the treating physician believes the treatment may provide

This license agreement combines Apricus’ expertise in men’s health with Forendo’s established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for

If approved, it would be the first pediatric combination vaccine in the US designed to help protect against six important diseases including diphtheria, tetanus, pertussis (whooping cough), polio

The US Food and Drug Administration (FDA) has approved Contrave as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with

In 2011, MedImmune licensed the OX40 agonist platform from AgonOx as a result of a partnership between the Providence Cancer Center and AgonOx, a spin-off company from the

The company said that the drug candidate in the ALS trial is called as GM604 and GM608 in the PD trial. For the treatment of ALS, the company

In a poster at the American Society of Human Genetics (ASHG) Annual Meeting, Daniel G. Bichet, M.D., M.Sc., Professor, Department of Physiology, University of Montreal, presented results from

The median number of injections using the protocol-specified retreatment regimen was one fewer in patients treated with EYLEA compared to bevacizumab and ranibizumab. Fewer patients in the EYLEA

Development of the vaccine candidate is progressing at an unprecedented rate, with first phase 1 safety trials with the vaccine candidate underway in the USA, UK and Mali,